
Preclinical Toxicology Report Synthesis & Regulatory Narrative
Transform preclinical toxicology data into GLP-compliant regulatory narratives
What You Can Do
You can rapidly convert complex multi-study toxicology datasets—clinical chemistry, hematology, histopathology, organ weights, and clinical observations—into structured, scientifically rigorous regulatory narratives. The skill identifies critical findings, flags inconsistencies, synthesizes dose-response relationships, and generates organ-system-specific toxicity summaries suitable for regulatory submissions, reducing manual narrative drafting from 30-50 hours to 8-12 hours per study.
Features
transforms study datasets into coherent safety profiles with proper scientific context
ensures narratives maintain regulatory standards and documentation requirements throughout drafting
generates targeted toxicity narratives for hepatic, renal, cardiac, immunotoxicity, and other organ systems
synthesizes findings across single-dose, repeated-dose, and specialized safety studies into unified safety profiles
identifies patterns and relationships between dose levels and observed toxicological findings
drafts human relevance statements and risk assessments with regulatory defensibility
produces IND/CTA-ready narratives for Toxicology and Chemistry, Manufacturing, Controls sections
identifies contradictions and data gaps that require resolution before submission
Example Output
Example 1: 90-Day Repeated-Dose Study Narrative
Input: Raw data from 90-day rat study (50, 150, 500 mg/kg/day doses) with clinical chemistry, histopathology, organ weights
Output:
Systemic Toxicity: At 500 mg/kg/day, animals exhibited dose-related increases in ALT (3.2× control) and AST (2.8× control) with correlating hepatocellular hypertrophy and minimal inflammation on histopathology. These findings were reversible upon 14-day recovery. NOAEL: 150 mg/kg/day.
Target Organ: Liver (based on clinical chemistry elevation and histomorphologic changes). Renal effects limited to minimal protein precipitation at 500 mg/kg/day without functional impairment.
Example 2: Cross-Study Safety Profile
Input: Single-dose (LD50 study), 28-day, 90-day, and 6-month chronic toxicology data
Output:
Safety Profile Summary: Consistent target organ toxicity pattern across all studies with liver as primary organ of concern. Dose-response relationship evident (linear at 50-500 mg/kg/day; plateau observed at higher exposures). No immunotoxicological signals or reproductive effects noted in any study. Human relevance: Rat hepatic metabolism parallels clinical CYP3A4 pathway; findings considered relevant to human safety assessment.
What's Included
- tox-report-synthesis SKILL.md: Detailed instruction file with data interpretation criteria and regulatory narrative standards
- Toxicology Data Template: Structured format for inputting study datasets (clinical chemistry, hematology, histopathology, organ weights, clinical observations)
- Regulatory Narrative Framework: Section-by-section outline for IND/CTA toxicology narratives with compliance checkpoints
- Findings Summary Checklist: QC checklist for dose-response consistency, organ-system coherence, and GLP documentation requirements
- Cross-Study Synthesis Workflow: Step-by-step guide for integrating multi-study datasets into unified safety profiles
Who It's For
- Toxicologists preparing preclinical safety documentation for regulatory submissions
- Regulatory Affairs Specialists synthesizing study data into IND/CTA narrative modules
- Drug Development Program Managers accelerating preclinical documentation timelines
- Contract Research Organization (CRO) Report Writers generating GLP-compliant study narratives at scale
- Pharmaceutical R&D Teams converting raw toxicology data into internally consistent safety assessments
Best For
- Study summary narratives from 14-day, 28-day, 90-day, and chronic toxicology studies
- Organ-system-specific toxicity narratives (hepatic, renal, cardiac, immunotoxicity, neurotoxicity)
- Cross-study safety profile synthesis spanning single-dose through chronic repeated-dose studies
- Regulatory narrative sections for IND, CTA, and other submission dossiers
- Risk characterization and human relevance statements with dose-response justification







